Thomson Reuters Teams with CHDI Foundation to Build Tools for Huntington’s Disease Research

The Intellectual Property & Science business of Thomson Reuters has announced a partnership with CHDI Foundation, Inc. to develop systems biology tools for Huntington’s disease (HD) research. There currently is no effective treatment for HD, which is a devastating neurodegenerative disorder that impacts muscle coordination and results in gradual cognitive decline and dementia. The collaboration will include reconstruction and analysis of causal networks underlying HD mechanisms and building a comprehensive collection of HD pathology pathway maps to help researchers around the world.

“Building a clearer, more detailed understanding of Huntington’s disease that leads to the development of therapies is CHDI’s top priority,” says Keith Elliston, vice president of systems biology at CHDI. “We are very pleased to be collaborating with Thomson Reuters to provide the whole HD research community with valuable tools that will further our knowledge of the disease and bring us closer to effective therapeutic options for patients.” For more information, click here to read the full release.